Chromosomal aberrations and their role in the transformation of chronic lymphocytic leukaemia in the era of BCR inhibitors treatment


Authors: H. Urbánková;  L. Krůzová;  M. Holzerová;  R. Urbanová;  P. Turcsányi;  T. Papajík
Authors‘ workplace: Hemato-onkologická klinika Lékařské fakulty Univerzity Palackého a Fakultní nemocnice Olomouc
Published in: Transfuze Hematol. dnes,1, 2020, No. Online only, p. 1-11.
Category:

Overview

The use of BCR signalling inhibitors has meant substantial progress in the treatment of relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL), especially with prognostically negative cytogenetic aberrations. However, there is still a subset of patients who transform to a more aggressive lymphoproliferative disease, so called Richter syndrome (RS). Effective treatment of RS patients is currently not available. Understanding the molecular nature of transformation is critical for developing new drugs and their combinations.

Keywords:

chronic lymphocytic leukaemia (CLL) – Richter syndrome (RS) – CDKN2A – TP53 – complex karyotype


Sources

1.         Rossi D, Gaidano G. Richter syndrome: molecular insights and clinical perspectives. Hematol Oncol 2009;27(1):1–10.

2.         Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues, revised 4thedition. Lyon: International Agency for Research on Cancer (IARC); 2017. 216–221 p.

3.         Maddocks KJ, Ruppert AS, Lozanski G, et al. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol 2015;1(1):80–87.

4.         Jain P, Keating M, Wierda W, et al. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood 2015;125(13):2062–2067.

5.         Ahn IE, Underbayev C, Albitar A, et al. Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. Blood 2017;129(11):1469–1479.

6.         Timar B, Fulop Z, Csernus B, et al. Relationship between the mutational status of VH genes and pathogenesis of diffuse large B-cell lymphoma in Richter's syndrome. Leukemia 2004;18(2):326–330.

7.         Rossi D, Spina V, Deambrogi C, et al. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood 2011;117(12):3391–3401.

8.         Brecher M, Banks PM. Hodgkin's disease variant of Richter's syndrome. Report of eight cases. Am J Clin Pathol 1990;93(3):333–339.

9.         Mao Z, Quintanilla-Martinez L, Raffeld M, et al. IgVH mutational status and clonality analysis of Richter's transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution. Am J Surg Pathol 2007;31(10):1605–1614.

10.       Jain P, O'Brien S. Richter's transformation in chronic lymphocytic leukemia. Oncology (Williston Park) 2012;26(12):1146–1152.

11.       Rossi D, Gaidano G. Richter syndrome: pathogenesis and management. Semin Oncol 2016;43(2):311–319.

12.       Fabbri G, Khiabanian H, Holmes AB, et al. Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome. J Exp Med 2013;210(11):2273–2288.

13.       Parikh SA, Kay NE, Shanafelt TD. How we treat Richter syndrome. Blood 2014;123(11):1647–1657.

14.       Rossi D, Spina V, Gaidano G. Biology and treatment of Richter syndrome. Blood 2018;131(25):2761–2772.

15.       Xiao W, Chen WW, Sorbara L, et al. Hodgkin lymphoma variant of Richter transformation: morphology, Epstein-Barr virus status, clonality, and survival analysis-with comparison to Hodgkin-like lesion. Hum Pathol 2016;55:108–116.

16.       Rossi D, Cerri M, Capello D, et al. Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome. Br J Haematol 2008;142(2):202–215.

17.       Doubek M, Špaček M, Pospíšilová Š, et al. Doporučení pro diagnostiku a léčbu chronické lymfocytární leukemie (CLL) – 2018 Transfuze Hematol dnes 2018;24(3):208–220.

18.       Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343(26):1910–1916.

19.       Chigrinova E, Rinaldi A, Kwee I, et al. Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. Blood 2013;122(15):2673–2682.

20.       Burger JA, Landau DA, Taylor-Weiner A, Bozic I, Zhang H, Sarosiek K, et al. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat Commun 2016;7:11589.

21.       Khan M, Siddiqi R, Thompson PA. Approach to Richter transformation of chronic lymphocytic leukemia in the era of novel therapies. Ann Hematol 2018;97(1):1–15.

22.       Ouillette P, Fossum S, Parkin B, et al. Aggressive chronic lymphocytic leukemia with elevated genomic complexity is associated with multiple gene defects in the response to DNA double-strand breaks. Clin Cancer Res 2010;16(3):835–847.

23.       Edelmann J, Holzmann K, Miller F, et al. High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations. Blood 2012;120(24):4783–4794.

24.       Papajík T, Urbanová R, Turcsányi P. Ohlédnutí za čtvrtstoletím léčby chronické lymfocytární leukemie. Transfuze Hematol dnes 2019;25(1):72–80.

25.       Miller CR, Ruppert AS, Heerema NA, et al. Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib. Blood Adv 2017;1(19):1584–1588.

26.       Urbánková H, Krůzová L, Holzerová M, et al. Chromozomové a genomické změny u pacientů s transformací chronické lymfocytární leukemie léčených inhibitory BCR signalizace. Sborník abstrakt XXXIII Olomoucké hematologické dny; 2019 26.–28. 5. 2019; Olomouc, Česká Republika. Olomouc: Univerzita Palackého v Olomouci; 2019.

27.       Woyach JA, Ruppert AS, Guinn D, et al. BTK(C481S)-mediated resistance to ibrutinib in chronic lymphocytic leukemia. J Clin Oncol 2017;35(13):1437–1443.

Labels
Haematology Internal medicine Clinical oncology
Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account